188 related articles for article (PubMed ID: 19519771)
21. Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer.
Wu Z; Zhang Z; Ge X; Lin Y; Dai C; Chang J; Liu X; Geng R; Wang C; Chen H; Sun M; Guo W; Li J
Oncotarget; 2015 Dec; 6(38):40519-34. PubMed ID: 26528757
[TBL] [Abstract][Full Text] [Related]
22. Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase.
Ma Q; Zhang K; Guin S; Zhou YQ; Wang MH
Mol Cancer; 2010 Nov; 9():307. PubMed ID: 21114864
[TBL] [Abstract][Full Text] [Related]
23. Curcumin blocks RON tyrosine kinase-mediated invasion of breast carcinoma cells.
Narasimhan M; Ammanamanchi S
Cancer Res; 2008 Jul; 68(13):5185-92. PubMed ID: 18593918
[TBL] [Abstract][Full Text] [Related]
24. A novel variant of the RON receptor tyrosine kinase derived from colorectal carcinoma cells which lacks tyrosine phosphorylation but induces cell migration.
Wang D; Lao WF; Kuang YY; Geng SM; Mo LJ; He C
Exp Cell Res; 2012 Dec; 318(20):2548-58. PubMed ID: 22975341
[TBL] [Abstract][Full Text] [Related]
25. Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein.
Wang MH; Montero-Julian FA; Dauny I; Leonard EJ
Oncogene; 1996 Nov; 13(10):2167-75. PubMed ID: 8950984
[TBL] [Abstract][Full Text] [Related]
26. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis.
Peace BE; Hughes MJ; Degen SJ; Waltz SE
Oncogene; 2001 Sep; 20(43):6142-51. PubMed ID: 11593422
[TBL] [Abstract][Full Text] [Related]
27. RON (recepteur d'origine nantais) expression and its association with tumor progression in laryngeal squamous cell carcinoma.
Kim SA; Yoon TM; Lee DH; Park YL; Lee KH; Lim SC; Joo YE; Lee JK
Auris Nasus Larynx; 2014 Apr; 41(2):201-6. PubMed ID: 24287326
[TBL] [Abstract][Full Text] [Related]
28. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.
Lu Y; Yao HP; Wang MH
Cancer Lett; 2007 Nov; 257(2):157-64. PubMed ID: 17889431
[TBL] [Abstract][Full Text] [Related]
29. A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.
Chakedis J; French R; Babicky M; Jaquish D; Howard H; Mose E; Lam R; Holman P; Miyamoto J; Walterscheid Z; Lowy AM
Oncogene; 2016 Jun; 35(25):3249-59. PubMed ID: 26477314
[TBL] [Abstract][Full Text] [Related]
30. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain.
Wang MH; Lao WF; Wang D; Luo YL; Yao HP
Cancer Biol Ther; 2007 Jul; 6(7):1121-9. PubMed ID: 17611409
[TBL] [Abstract][Full Text] [Related]
31. Macrophage stimulating protein preserves blood brain barrier integrity after intracerebral hemorrhage through recepteur d'origine nantais dependent GAB1/Src/β-catenin pathway activation in a mouse model.
Lu T; Wang Z; Prativa S; Xu Y; Wang T; Zhang Y; Yu L; Xu N; Tang J; You W; Chen G; Zhang JH
J Neurochem; 2019 Jan; 148(1):114-126. PubMed ID: 30380151
[TBL] [Abstract][Full Text] [Related]
32. Integrative genomic analyses of recepteur d'origine nantais and its prognostic value in cancer.
Yu H; Yuan J; Xiao C; Qin Y
Int J Mol Med; 2013 May; 31(5):1248-54. PubMed ID: 23483216
[TBL] [Abstract][Full Text] [Related]
33. Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues.
Zhou D; Pan G; Zheng C; Zheng J; Yian L; Teng X
BMC Cancer; 2008 Nov; 8():353. PubMed ID: 19040718
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase.
Wang MH; Wang D; Chen YQ
Carcinogenesis; 2003 Aug; 24(8):1291-300. PubMed ID: 12807733
[TBL] [Abstract][Full Text] [Related]
35. RON and RONΔ160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with β-catenin.
Zhou D; Huang L; Zhou Y; Wei T; Yang L; Li C
Aging (Albany NY); 2019 May; 11(9):2735-2748. PubMed ID: 31085796
[TBL] [Abstract][Full Text] [Related]
36. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.
Thomas RM; Toney K; Fenoglio-Preiser C; Revelo-Penafiel MP; Hingorani SR; Tuveson DA; Waltz SE; Lowy AM
Cancer Res; 2007 Jul; 67(13):6075-82. PubMed ID: 17616662
[TBL] [Abstract][Full Text] [Related]
37. The MSP-RON axis stimulates cancer cell growth in models of triple negative breast cancer.
Millar R; Kilbey A; Remak SJ; Severson TM; Dhayade S; Sandilands E; Foster K; Bryant DM; Blyth K; Coffelt SB
Mol Oncol; 2020 Aug; 14(8):1868-1880. PubMed ID: 32484599
[TBL] [Abstract][Full Text] [Related]
38. Effect of Recepteur d'Origine Nantais expression on chemosensitivity and tumor cell behavior in colorectal cancer.
Kim N; Cho SB; Park YL; Park SY; Myung E; Kim SH; Yu HM; Son YA; Myung DS; Lee WS; Joo YE
Oncol Rep; 2016 Jun; 35(6):3331-40. PubMed ID: 27035413
[TBL] [Abstract][Full Text] [Related]
39. Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi).
Zou Y; Howell GM; Humphrey LE; Wang J; Brattain MG
PLoS One; 2013; 8(7):e69992. PubMed ID: 23922886
[TBL] [Abstract][Full Text] [Related]
40. The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation.
Angeloni D; Danilkovitch-Miagkova A; Miagkov A; Leonard EJ; Lerman MI
J Biol Chem; 2004 Jan; 279(5):3726-32. PubMed ID: 14597639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
